STAT3 and hematologic disorder: In that PPARγ agonists inhibit the IL-6-regulated Stat3 signaling cascade, a role for PPARγ agonists in regulating expression of miRNAs critical to the pathogenesis of hematological malignancies may be an important avenue of future scientific investigations.